DIVISLAB:NSE:NSE-Divi's Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 5469.15

Change

+16.95 (+0.31)%

Market Cap

USD 1,451.89B

Volume

0.21M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India. Address: Divi Towers, Hyderabad, India, 500032

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-30.10 (-1.61%)

USD 4,371.22B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-93.65 (-2.71%)

USD 1,161.24B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-31.00 (-2.79%)

USD 1,125.52B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-63.85 (-0.96%)

USD 1,094.10B
LUPIN:NSE Lupin Limited

-45.45 (-2.00%)

USD 1,011.50B
MANKIND:NSE Mankind Pharma Ltd

-59.85 (-2.44%)

USD 1,001.78B
AUROPHARMA:NSE Aurobindo Pharma Limited

-13.30 (-0.86%)

USD 893.94B
ALKEM:NSE Alkem Laboratories Limited

-126.55 (-2.04%)

USD 728.19B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-66.95 (-3.91%)

USD 480.90B
AJANTPHARM:NSE Ajanta Pharma Limited

-27.85 (-0.88%)

USD 390.03B

ETFs Containing DIVISLAB:NSE

KMED 0.00 % 0.79 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.67% 56% F 68% D+
Dividend Return 0.77% 65% D 58% F
Total Return 40.43% 57% F 69% C-
Trailing 12 Months  
Capital Gain 44.70% 41% F 56% F
Dividend Return 0.79% 62% D 52% F
Total Return 45.50% 41% F 56% F
Trailing 5 Years  
Capital Gain 233.90% 48% F 52% F
Dividend Return 6.72% 65% D 48% F
Total Return 240.62% 52% F 51% F
Average Annual (5 Year Horizon)  
Capital Gain 23.09% 38% F 33% F
Dividend Return 23.64% 37% F 33% F
Total Return 0.55% 51% F 46% F
Risk Return Profile  
Volatility (Standard Deviation) 42.42% 60% D- 60% D-
Risk Adjusted Return 55.72% 46% F 33% F
Market Capitalization 1,451.89B 99% N/A 97% N/A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector